William Hampton Bradley MD
Gynecologic Oncology
Assistant Professor, Obstetrics & Gynecology, Medical College of Wisconsin
Join to View Full Profile
Medical College of Wisconsin8701 Watertown Plank RoadMilwaukee, WI 53226
Phone+1 414-805-6606
Fax+1 414-805-2233
Dr. Bradley is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Gynecologic Oncology, 2005 - 2008
University of MinnesotaResidency, Obstetrics and Gynecology, 2000 - 2004- University of Minnesota Medical SchoolClass of 2000
Certifications & Licensure
WI State Medical License 2008 - 2027
NY State Medical License 2005 - 2008
MN State Medical License 2002 - 2006
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
- Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
- Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer Start of enrollment: 2012 Jun 01
Publications & Presentations
PubMed
- Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings.Premal H Thaker, Stacy R Lindborg, Ana Limon, Douglas V Faller, William H Bradley
Expert Opinion on Investigational Drugs. 2026-03-01 - Corrigendum to "OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients...Premal H Thaker, Debra L Richardson, Andrea R Hagemann, Robert W Holloway, Mark Reed
Gynecologic Oncology. 2025-12-01 - 8 citationsOVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed...Premal H Thaker, Debra L Richardson, Andrea R Hagemann, Robert W Holloway, Mark Reed
Gynecologic Oncology. 2025-06-01
Press Mentions
UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive ManagementSeptember 10th, 2024- IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive ManagementSeptember 9th, 2024
- Different Outcomes for Oshkosh Sisters in Cancer Drug TrialApril 30th, 2021
Grant Support
- Medical College of Wisconsin Lead Academic Participating Site RenewalMEDICAL COLLEGE OF WISCONSIN2019–2032
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
